Value through Innovation20 April 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

05.12.2012

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session

- For Non-US, Non-UK & Non-Canadian Media Only
14.11.2012

Run for diabetes: Boehringer Ingelheim supports ‘Life for a Child’ programme on World Diabetes Day

13.11.2012

Boehringer Ingelheim and BaroFold Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology

12.11.2012

Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner’s proprietary pipeline with clinical supply of DARPin® molecules

10.11.2012

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease

- For media outside of the U.S.A., U.K. and Canada only
08.11.2012

Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes

- For Non-U.S. and Non-U.K. Media
08.11.2012

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF

- For Non-US, Non-UK & Non-Canadian Media Only
06.11.2012

Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement

05.11.2012

Pradaxa® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations

- For Non-US, Non-UK & Non-Canadian Media Only
05.11.2012

FDA and EMA reaffirm important health benefits and safety of Pradaxa® (dabigatran etexilate) for patients with atrial fibrillation

- For Non-US, Non-UK & Non-Canadian Media Only
31.10.2012

Wealth of worldwide evidence on Pradaxa® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions

- For Non-US, Non-UK & Non-Canadian Media Only
31.10.2012

Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D

26.10.2012

The Respimat® success story: Boehringer Ingelheim doubles its production capacity

26.10.2012

European approval granted for Trajenta® (linagliptin) tablets as add-on therapy to insulin in adults with Type 2 Diabetes

- For Non-U.S. and Non-U.K. Media
11.10.2012

NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms

- For non-US media only
11.10.2012

Boehringer Ingelheim congratulates Nobel Prize winner Prof. Brian Kobilka

04.10.2012

Final Phase IIb interferon-free hepatitis C data from Boehringer Ingelheim to be presented at AASLD

- For media outside of the U.S.A. only
02.10.2012

Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies

- EX US & UK. Medical Media Only.